Drugs / Ziprasidone
Ziprasidone
also known as
Geodon · ziprasidone hydrochloride · CP-88, 059-27 · CP-88,059-1 · CP-88059 · NSC-760351 · Zeldox · ZIP · +10 more
Small molecule targets DRD2, HTR2A, HTR2C via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | GEODON | — | 2004-08-19 – 2022-01-28 | fda.gov ↗ |
| Approved | US (FDA) | GEODON | — | 2001-02-05 | fda.gov ↗ |
Trials 80 · started per year
today
US approved 2001
2
3
8
14
5
5
12
2
7
3
4
2
3
2
1
2
1
2
1
1
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04587115 | Jun 2017 → Jun 2019 | drug dependence | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03781115 | Nov 2017 → Feb 2027 expected | schizophrenia | University of Arizona | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02650102 | Jan 2013 → Dec 2016 | schizophrenia | Shanxi Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04975035 | Jan → Jul 2012 | schizophrenia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Terminated | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT00633399 | Jul 2008 → Mar 2014 | major depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00635700 | Mar 2008 → Nov 2012 | psychotic disorder | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00676429 | Jul 2006 → Jun 2008 | conduct disorder, oppositional defiant disorder | University Hospital Freiburg | Completed | No outcome recorded |
| Phase 2 | NCT00215150 | Nov 2004 → Dec 2008 | social phobia | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT01006551 | Dec 2002 → Feb 2006 | schizophrenia | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT00208559 | Feb 2002 → Jun 2005 | autism | Drexel University College of Medicine | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00395031 | Sep 2003 → Jan 2010 | schizoaffective disorder, schizophrenia | Manhattan Psychiatric Center | Completed | No outcome recorded |
| Phase 328 trials | ||||||
| Phase 3 | NCT03768726 | Dec 2018 → Jul 2020 | bipolar disorder | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02075047 | May 2014 → Apr 2020 | bipolar I disorder | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01765829 | Nov 2012 → Nov 2015 | psychotic disorder | Fundación Pública Andaluza Progreso y Salud | Unknown | No outcome recorded |
| Phase 3 | NCT01211522 | Dec 2011 → Aug 2017 | delirium, mental disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01124877 | Jul 2010 → Oct 2011 | bipolar disorder | Viatris Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01113541 | Jul 2010 → Feb 2011 | bipolar disorder | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00723606 | Sep 2008 → Jul 2009 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00483548 | Oct 2007 → Dec 2008 | bipolar I disorder, bipolar depression | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00347425 | Dec 2006 → Feb 2008 | schizophrenia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00265382 | Jun 2006 → Jun 2009 | schizophrenia | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00421954 | May 2006 → May 2008 | bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 3 | NCT00312494 | Apr 2006 → Dec 2008 | bipolar disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00265330 | Mar 2006 → Jan 2008 | bipolar disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00403546 | Jan 2006 → May 2011 | schizophrenia | Donald C. Goff, MD | Completed | No outcome recorded |
| Phase 3 | NCT00257166 | Jan 2006 → Jul 2007 | bipolar disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00280566 | Dec 2005 → May 2008 | bipolar I disorder, manic bipolar affective disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00197951 | Oct 2004 → Apr 2007 | alcohol dependence, anxiety, depressive disorder | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT00645229 | Sep 2004 → Mar 2005 | schizoaffective disorder, schizophrenia | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00645372 | Jul 2004 → May 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00143351 | Jun 2003 → Sep 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00645515 | Jun → Dec 2003 | schizophrenia | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00145444 | Mar 2003 → Nov 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00136994 | Mar 2003 → Nov 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00649844 | Jan 2003 → Sep 2004 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00139737 | Mar 2002 → Jun 2009 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00159770 | Nov 2001 → Sep 2004 | schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00174447 | Oct 2001 → Oct 2008 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 437 trials | ||||||
| Phase 4 | NCT04446234 | May 2021 → Dec 2022 | schizophrenia | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT02935998 | Oct 2016 → Dec 2017 | schizophrenia | Yang Fude | Unknown | No outcome recorded |
| Phase 4 | NCT02307396 | Feb 2015 → Jun 2016 | schizoaffective disorder, schizophrenia | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT01893229 | Sep 2013 → Dec 2015 | bipolar disorder | Guiyun Xu | Unknown | No outcome recorded |
| Phase 4 | NCT01293825 | Jan 2011 → Aug 2012 | bipolar disorder | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01198353 | Sep 2010 → Jun 2013 | schizoaffective disorder, schizophrenia | Soonchunhyang University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01172652 | Apr 2010 → Oct 2011 | bipolar disorder, generalized anxiety disorder, panic disorder | VA Palo Alto Health Care System | Completed | No outcome recorded |
| Phase 4 | NCT01016145 | Apr 2009 → Jun 2010 | psychotic disorder | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT00835107 | Feb 2009 → Jun 2011 | bipolar depression | Queen's University | Completed | No outcome recorded |
| Phase 4 | NCT00748566 | Dec 2008 → May 2012 | psychotic disorder | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00786318 | Sep 2008 → Jul 2011 | delirium, psychotic disorder | George Washington University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01000402 | Feb 2008 → Oct 2012 | attention deficit-hyperactivity disorder, bipolar disorder | Federal University of Rio Grande do Sul | Unknown | No outcome recorded |
| Phase 4 | NCT00472641 | Jan 2007 → Dec 2009 | bipolar disorder | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00329108 | Nov 2006 → Jul 2007 | manic bipolar affective disorder | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00406315 | Nov 2006 → Dec 2008 | schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00338949 | Jun 2006 → Dec 2009 | metabolic syndrome X, schizophrenia | Veterans Medical Research Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00374543 | Feb 2006 → Oct 2007 | bipolar disorder, generalized anxiety disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00458211 | May 2005 → Apr 2008 | schizoaffective disorder, schizophrenia | Bronx Psychiatric Center | Completed | No outcome recorded |
| Phase 4 | NCT00297960 | Apr 2005 → ? | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00237666 | Feb 2005 → Feb 2008 | bipolar II disorder, major depressive disorder | The Medical Research Network | Completed | No outcome recorded |
| Phase 4 | NCT00351000 | Jan 2005 → Mar 2007 | schizophrenia | North Suffolk Mental Health Association | Completed | No outcome recorded |
| Phase 4 | NCT00137020 | Nov 2004 → Apr 2006 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00199940 | Dec 2003 → Apr 2007 | mood disorder, schizophrenia | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 4 | NCT00649064 | Dec 2003 → Sep 2004 | schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00224315 | Nov 2003 → Sep 2006 | schizophrenia | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| Phase 4 | NCT00159757 | Nov 2003 → Feb 2005 | schizophrenia | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00650429 | Oct 2003 → May 2005 | schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00645320 | Aug 2003 → Aug 2004 | psychotic disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00644800 | Jul 2003 → May 2004 | delusional disorder, manic bipolar affective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00239109 | Apr 2003 → Feb 2007 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00208208 | Dec 2002 → Apr 2005 | post-traumatic stress disorder | Creighton University | Completed | No outcome recorded |
| Phase 4 | NCT00048802 | Aug 2002 → Aug 2006 | bipolar disorder | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT00181922 | Mar 2002 → Dec 2004 | manic bipolar affective disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00418171 | Feb 2002 → Apr 2007 | schizophrenia | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00034801 | Sep 2001 → Mar 2003 | depressive disorder, schizoaffective disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00014001 | Dec 2000 → Dec 2004 | schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT01157559 | ? → Jun 2008 | schizophrenia | Chonbuk National University Hospital | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT04076371 | Jan 2012 → Dec 2018 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT00818298 | Jan 2009 → Jan 2011 | schizoaffective disorder, schizophrenia | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| — | NCT00225498 | Jun 2002 → Oct 2008 | schizophrenia | Northwell Health | Completed | No outcome recorded |
| — | NCT00205725 | Nov 2000 → Oct 2006 | schizophrenia, type 2 diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
Also used as a comparator or background therapy in 46 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03837860 Comparator | Apr 2019 → Mar 2021 | opiate dependence, opioid abuse | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT03565068 Background | Jun 2018 → Apr 2020 | schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03011645 Comparator | May 2018 → Jan 2020 | cardiovascular disorder | Duke University | Terminated | No outcome recorded |
| Phase 1 | NCT02181803 Background | Aug 2014 → Apr 2015 | schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00821444 Comparator | Jan → Mar 2009 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT03557931 Background | Jul 2018 → Oct 2019 | schizophrenia | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03319953 Background | Dec 2017 → Sep 2019 | schizophrenia | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT00555997 Comparator | Mar 2008 → Jun 2010 | major depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00509067 Background | Nov 2007 → Mar 2011 | schizophrenia | Georgetown University | Completed | No outcome recorded |
| Phase 2 | NCT00490542 Comparator | Dec 2006 → Aug 2009 | bipolar depression | Tufts Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00096863 Comparator | Dec 2004 → Jul 2007 | delirium | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT00635921 Comparator | Mar 2004 → Apr 2006 | borderline personality disorder | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00650611 Comparator | Dec 2003 → Mar 2005 | bipolar disorder, schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00340379 Comparator | Apr 2003 → Aug 2005 | mood disorder | Duke University | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT01117220 Comparator | Jun 2010 → Apr 2011 | bipolar disorder | Viatris Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT00257192 Comparator | Apr 2006 → Mar 2009 | schizophrenia | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00282464 Comparator | Feb 2006 → Mar 2008 | bipolar I disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00288353 Comparator | Jan 2006 → Dec 2008 | bipolar disorder, schizoaffective disorder, schizophrenia | Northwestern University | Terminated | No outcome recorded |
| Phase 3 | NCT00254202 Comparator | Nov 2005 → Sep 2006 | schizophrenia | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00141271 Comparator | Jul 2005 → Feb 2008 | bipolar disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00177164 Comparator | Nov 2003 → Mar 2008 | bipolar I disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT05741502 Comparator | Aug 2023 → Jan 2026 | schizophrenia | Ohio State University | Terminated | No outcome recorded |
| Phase 4 | NCT02282085 Comparator | Dec 2014 → Dec 2017 | schizophrenia | Matt Byerly | Unknown | No outcome recorded |
| Phase 4 | NCT02237417 Comparator | Sep 2014 → Nov 2018 | schizophrenia | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT02040883 Background | Feb → Dec 2014 | schizophrenia | Qingyun Yin | Unknown | No outcome recorded |
| Phase 4 | NCT01844700 Comparator | Jul 2013 → Apr 2014 | obesity due to melanocortin 4 receptor deficiency | Northwell Health | Terminated | No outcome recorded |
| Phase 4 | NCT01185743 Comparator | Jul 2010 → Jan 2017 | diabetes mellitus, schizophrenia | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01168674 Comparator | Feb 2010 → Dec 2011 | bipolar disorder, major depressive disorder | Tufts Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01714011 Comparator | May 2009 → Sep 2011 | schizophrenia | University of Malaya | Completed | No outcome recorded |
| Phase 4 | NCT00806234 Comparator | Jan 2009 → Mar 2014 | psychotic disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT02526030 Comparator | Oct 2008 → Feb 2014 | schizophrenia | Fundación Marques de Valdecilla | Completed | No outcome recorded |
| Phase 4 | NCT00622739 Comparator | Feb 2007 → Sep 2009 | bipolar disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00330863 Comparator | May 2006 → Jan 2011 | schizoaffective disorder, schizophrenia | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT02534363 Comparator | Oct 2005 → Jan 2011 | schizophrenia | Fundación Marques de Valdecilla | Completed | No outcome recorded |
| Phase 4 | NCT02305823 Comparator | Oct 2005 → Feb 2011 | schizophrenia | Fundación Marques de Valdecilla | Completed | No outcome recorded |
| Phase 4 | NCT00634348 Comparator | Apr 2004 → Mar 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00148564 Comparator | Mar 2004 → Mar 2007 | schizophrenia | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00932529 Comparator | Feb 2003 → Jan 2010 | psychotic disorder | University of Bergen | Completed | No outcome recorded |
| Phase 4 | NCT00044655 Comparator | Jul 2001 → Mar 2009 | schizophrenia | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT02192723 Comparator | Jun 2012 → Jun 2014 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT01485692 Comparator | Feb 2009 → Mar 2011 | — | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT00910988 Comparator | Feb 2009 → Jun 2012 | hyperglycemia, hyperlipidemia | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00538642 Comparator | Aug 2007 → Apr 2011 | bipolar disorder, schizoaffective disorder, schizophrenia | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| — | NCT00288366 Comparator | Jan 2006 → Dec 2008 | bipolar disorder, schizoaffective disorder, schizophrenia | Northwestern University | Completed | No outcome recorded |
| — | NCT00229385 Comparator | Jan 2006 → Apr 2008 | obsessive-compulsive disorder, schizophrenia | Sheba Medical Center | Completed | No outcome recorded |
| — | NCT00515723 Comparator | Sep 2001 → Dec 2008 | hyperglycemia, schizoaffective disorder, schizophrenia, type 2 diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 127 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ziprasidone | “Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗124“There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment...” NCT00159757 ↗ “Thirty patients will receive ziprasidone treatment, in progressively increasing doses, starting from 40 mg per day, and the other 30 patients will receive placebo” NCT00197951 ↗ “Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.” NCT03319953 ↗ “Including Olanzapine, Risperidone, Paliperidone, Quetiapine, Aripiprazole, Ziprasidone, Lurasidone, Cariprazine, and all Typical antipsychotics” NCT05741502 ↗ “Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.” NCT00338949 ↗ “Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder” NCT00177164 ↗ “Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg” NCT01016145 ↗ “Ziprasidone is an atypical antipsychotic recommended to be administered twice daily.” PMID 23417515 ↗ Feb 2013 “switched to Zoladine capsules (ziprasidone hydrochloride capsules)” NCT04975035 ↗ “Ziprasidone(according to response, and tolerance)40-160mg” NCT01000402 ↗ “or ziprasidone) throughout the study.” NCT03565068 ↗ “ziprasidone HCI(Geodon®)” NCT02237417 ↗ “Geodon (Ziprasidone)” NCT00141271 ↗ “or Ziprasidone.” NCT02181803 ↗ |
| Known as | CP-88, 059-27 | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | CP-88,059-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | CP-88059 | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Geodon | “Patients will be switched from their current antipsychotic medication to aripiprazole (Abilify) or ziprasidone (Geodon) (unless clinically contraindicated) for comparison with...” NCT00288366 ↗13“The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently...” NCT00237666 ↗ “This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed.” NCT00282464 ↗ “This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients” NCT00421954 ↗ “Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Ablify)” NCT00177164 ↗ “Geodon (Ziprasidone) for Posttraumatic Stress Disorder” NCT00208208 ↗ “ziprasidone HCI(Geodon®)” NCT02237417 ↗ “ziprasidone (Geodon)” NCT00288353 ↗ “ziprasidone (Geodon)” NCT00490542 ↗ “ziprasidone (Geodon)” NCT00181922 ↗ “ziprasidone/Geodon” NCT00910988 ↗ “Ziprasidone/Geodon” NCT00472641 ↗ “Geodon, Zeldox” NCT00650429 ↗ |
| Known as | NSC-760351 | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Zeldox | “Geodon, Zeldox” NCT00650429 ↗ |
| Known as | ZIP | “5. 220 begin double-blind treatment with ziprasidone (ZIP)” NCT00014001 ↗ |
| Known as | Zipradon | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Ziprasidona | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | ziprasidone HCI | “ziprasidone HCI(Geodon®)” NCT02237417 ↗ |
| Known as | ziprasidone hydrochloride | “switched to Zoladine capsules (ziprasidone hydrochloride capsules)” NCT04975035 ↗ |
| Known as | Ziprasidone hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Ziprasidone hydrochloride monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Ziprasidone mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Ziprasidone mesilate trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | ZIPRASIDONE MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Ziprasidone mesylate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Zoladine | “switched to Zoladine capsules (ziprasidone hydrochloride capsules)” NCT04975035 ↗ |
| Action | Inhibit | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL708 ↗ |
| Modality | Small molecule | — CHEMBL708 ↗ |
| Route | Oral | “oral liquid formulations of haloperidol versus ziprasidone versus placebo” NCT00096863 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL708 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL708 ↗ |
| Target | HTR2C | “antagonist (ziprasidone) to reduce cortisol response to mental and metabolic stress in men carrying the rs6318 C allele and women in the rs6318 CC genotype of 5HTR2C.” NCT03011645 ↗ |